|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 17, Num. 1, 2000, pp. 52
|
ba00016
Biotecnologia Aplicada 2000; Vol. 17 No. 1, pp. 52
Large-scale Production of recombinant
Hepatitis B Surface Antigen from Pichia pastoris
Eugenio Hardy, Eduardo Martínez, David Diago,
Raúl Díaz, Daniel González, Luis Herrera
Centro de Ingeniería Genética y
Biotecnología, Apartado Postal 6162, Ciudad de La Habana, CP
10600, Cuba. Fax: (53-7) 218070 E-mail: ehardy@cigb.edu.cu
Code Number: BA00016
Introduction
An downstream process for the purification of HBsAg produced in
Pichia pastoris was established first at laboratory scale
[1] and further scaled-up from about 250- to 500-fold [2]. However,
the effectiveness of the key steps for the large-scale production
of P. pastoris-derived HBsAg had not been described
yet.
We analyze here the performance of our production technology in
terms of its ability to both render a highly pure HBsAg and remove
most of the intrinsic (yeast total proteins, nucleic acids,
carbohydrates, lipids) and extrinsic (immunopurification released
immunoglobulin [lg] G, endotoxin) contaminants. The results
obtained verified that this technology satisfies most of the World
Health Organization (WHO) requirements for the safe purification of
yeast-derived, biologically-active HBsAg particles. Consequently,
the vaccine (HEBERBIOVAC HB, Heberbiotec SA, Cuba), which is
formulated with P. pastoris-derived
HbsAg, has proven to be safe and efficacious, providing
protection against hepatitis B infection [3]
Methods
Ten independent industrial batches of HBsAg, five made in 1993
and five in 1998, were obtained as previously described [2 and
citations therein]. Briefly, the recombinant P. pastoris
yeast strain was kept as a master seed lot at -70 ºC to
guarantee that each bioreaction run was started from the same
original preparation. Under carefully controlled multiplication
conditions, the HBsAg gene-containing yeast cells were passed from
shake flasks into medium-scale bioreactors, and finally into a
large-scale bioreaction unit. After harvesting, the yeast cells
were disrupted to recover and purify HBsAg by a series of
well-established steps [2 and citations therein] These included
acid precipitation, adsorption/desorption from diatomaceous earth
matrix and, finally, successive purification through
immunoaffinity, ion-exchange and gel-filtration chromatographic
procedures. Each step was currently checked to be within
specifications of the WHO guidelines for quality and/or in-process
control procedures approved by the National Control Authority.
Also, the quality of the water and al buffer solutions were
monitored for conductivity, pH and microbiological or pyrogenic
contaminants, and were strictly controlled.
Results and Discussion
The ability of the P. pastoris-based technology
for large-scale production of recombinant hepatitis B virus surface
antigen (HBsAg) and to both reproducibly purify HBsAg and remove
most of the relevant contaminants was ascertained by evaluating 10
industrial production batches: 5 in 1993 and 5 in 1998. At an early
stage, the clarification of mechanically disrupted yeast cells by
acid precipitation rendered HBsAg with a purity as low as
3.8 ± 0.6%. However, by adsorption/desorption from
diatomaceous earth matrix, the purity of HBsAg rapidly increased to
18.8 ± 5%, which is suitable for chromatographic
processing. This step also eliminated non-particulated forms of
HBsAg, significantly lowered the amount of carbohydrates and
lipids, and concentrated the HBsAg 4.8-fold. Finally, a sequential
purification procedure that included large-scale immunoaffinity,
ion-exchange, and size-exclusion chromatographies further purified
the preparation, resulting in a product (HBsAg at a concentration
of 1.3 ± 0.2 g/L) with a purity of 95% or more.
Furthermore, each of the other contaminants measured reached the
following low levels per 20 mg HBsAg: host deoxyribonucleic
acid (less than 10 pg), carbohydrates (1.2 ± 0.02
mg), lipids (14 ± 0.28 mg),
immunopurification-released IgG (less than 100 ppm), and endotoxins
(106.7 ± 19.3 pg). These values were below those
specified for recombinant DNA hepatitis B vaccines according to WHO
guidelines.
References
Paper selected from Biotecnología Habana'99
Congress. November 28-December 3, 1999.
1. Pentón E. 1992 Procedure for the obtainment
of the hepatitis B virus recombinant surface antigen with a higher
immunogenic quality and its use as a vaccine. European Patent
Publication No. EP 480525.
2. Pérez L, López S, Beldarraín A, Arenal
D, Pentón E. Purification of recombinant hepatitis B surface
antigen (rec-HBsAg) from P. pastoris: A process development
study. In: Galindo E, Ramírez OT (Eds.), Advances in
Bioprocess Engineering. Kluwer Academic Publishers, Netherlands,
1994;pp.527-34.
3. Pentón E, Muzio V, Griego-González M. The
hepatitis B virus (HBV) infection and its prevention by a
recombinant-DNA viral surface antigen (rec-HBsAg) vaccine.
Biotecnología Aplicada 1994;11:1-11.
Copyright 2000 Elfos Scientiae
|